According to the latest data, covid shots might not stop at 3rd dose and boosters if necessary, as CDC claims that a 4th COVID-19 shot could be in the works for those who are mildly or severely at risk from fatal infections.
The CDC continued, urging those who have taken their first two shots to take the next one if 4 weeks have elapsed since taking the final one.
To be qualified as immunocompromised, one must be in active cancer treatment for blood cancers or tumors or be an organ transplant patient or stem cell recipient.
Recent studies have shown that there are over 9 million US citizens who are treated as immunocompromised, while another statistic shows that despite being vaccinated, immunocompromised people are still almost 500 times more likely to be hospitalized or die from COVID-19 related symptoms.
This brings up the question of the necessity of any further vaccine dosages, as we, the general public, were first told there would be 2, then 3, and now even a fourth vaccine shot all within a year.
When will the need for further vaccination end or was it all just one big ploy from the start?
Pharma company stocks have more than tripled in value since the pandemic has begun, leaving many wondering where this all will take us.
Following last week’s approval of booster shots and mixing and matching of separate vaccines, Rochelle Walensky, the director of the CDC, commented on the matter, mentioning that we must remain humble as our knowledge of this virus has increased substantially in the past 20 months, yet it feels like we still don’t know anything about it.
The CDC advisory panel, comprised mainly of people outside the regulatory agency urged endangered age groups to get booster shots, not referring to any specific brand, but rather just the option of the booster shot itself.
As for those vaccinated with the J&J dosage, a booster is recommended for everyone who has received the jab as the vaccine proved to be much less effective at stopping infection than its competitors Moderna and Pfizer.
The advisory panel continued debating and came to a 17-for 0-against (with one abstaining) decision on allowing the authorization of the Pfizer jab for children aged 5 to 11 years old.
As the advisory panel’s decisions aren’t binding, nothing can be said for sure, but some claim that it is a step in the right direction.
The public, however, did not like this idea as many have stated that even if vaccines would be authorized for children, they wouldn’t let their child be vaccinated just yet, a perfectly reasonable mindset considering the risks a vaccine brings with it, especially in young males, as there have been many documented cases of heart inflammation after administering an mRNA vaccine, like Pfizer’s to a child.
To absolve any concerns, Pfizer had set up several projections, using the data from previous research, to present the risk-reward factor a vaccine brings.
While the fact still remains that the risks of displaying these symptoms are much higher for those who have previously contracted the virus, it’s a risk not many parents are willing to take.
Following in Pfizer’s footsteps, Moderna is also working on getting its shot authorized for children.
In the end, it would appear it all boils down to who walks out of this pandemic with the most cash in their pockets, and big pharma is definitely the one to be keeping an eye on.